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Splenectomy as Part of Primary Cytoreductive Surgery
for Advanced Ovarian Cancer
A Retrospective Cohort Study
Ignacio Zapardiel, MD, PhD, Michele Peiretti, MD, PhD, Vanna Zanagnolo, MD, Roberto Biffi, MD,
Luca Bocciolone, MD, Fabio Landoni, MD, Giovanni Aletti, MD, Nicoletta Colombo, PhD,
and Angelo Maggioni, MD
Background: The aim of surgical approach in advanced ovarian cancer should be the
complete removal of all visible disease. Our purpose was to compare perioperative features
and postoperative complications, and secondarily oncological outcomes, between patients
who underwent splenectomy and those who did not at the time of surgery.
Materials and Methods: Thirty-three subjects underwent splenectomy, and we selected
99 controls with similar surgical characteristics but who did not undergo splenectomy. Data
collected included perioperative details and follow-up data.
Results: Longer operating time (33 minutes longer; P = 0.02), larger estimated blood loss
(812 mL more; P = 0.03), higher rate of intraoperative blood transfusions (78.8% vs 42.4%;
P G 0.01), and intensive care unit stay (1.4 vs 0.5 days; P G 0.01) as well as higher pneumonia
rate (2% vs 0%; P = 0.01) were observed in the splenectomy group. Disease-free and overall
survival rates were 30.3% and 66.6%, respectively, in the splenectomy group, and 33.3% and
59.6%, respectively, in the control group.
Conclusions: Splenectomy at the time of primary cytoreductive surgery for advanced
ovarian cancer may contribute to achieve complete cytoreduction with low perioperative
complication rate. This procedure seems to be an acceptable and rational intervention to
increase the survival rates of those patients.
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O varian cancer has the highest fatality-to-case ratio of allgynecologic cancers, as 62% of cases are diagnosed in
advanced-stage disease; 21,880 new cases and 13,850 deaths
are estimated during 2010 in the United States, which makes
this malignancy the fifth cancer related cause of death in
females.1
Standard approach of patients with advanced ovarian
cancer should be primary cytoreduction followed by platinum-
based chemotherapy.2Y4 The aim of surgical approach should
be the complete removal of all visible disease that would im-
prove the oncological results. However, owing to technical
reasons as well as a lack of surgeon experience, this objective
is not always reached5Y7 because optimal treatment may re-
quire extensive and complicated procedures in the upper ab-
domen such as liver or pancreatic resection.8 In those cases,
when complete cytoreduction cannot be achieved, neoad-
juvant chemotherapy treatment seems to be preferable, in-
stead of primary debulking surgery.9 Moreover, biology and
tumoral histology play an important role in the development
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and extension of the disease, and it has to be taken into
account at the time of first treatment.
Splenic metastasis occurs rarely in malignant tumors.
Based on studies of various tumors, the prevalence of splenic
metastasis has been reported as ranging from 2.3% to 7.1%.10
The exact incidence of splenic metastasis in ovarian cancer is
hard to determine. A study on 428 autopsies on patients with
various histologic types of ovarian cancer noted splenic me-
tastasis to be as high as 20%.11 Usually, the disease does not
invade the splenic parenchyma; however, the capsule of the
spleen and the splenic flexure of the colon along with the
gastrocolic ligament may be more commonly affected. Oc-
casionally, it is necessary to remove an intact spleen to remove
the whole tumoral mass.12Y14 This procedure could increase
the rate of intraoperative complications as well as postoper-
ative morbidity. Most of the evidence comes from case reports
and only few published studies. Because of that, neoadjuvant
treatment could have a role to avoid splenectomy, although by
the moment, no information has been published assessing that.
Because of it, splenectomy still seems to be the best option
to achieve the complete cytoreduction of the malignancy.
The objective of this study was to compare periop-
erative features and postoperative complications between
patients who underwent splenectomy and those who did not
at the time of primary cytoreductive surgery for advanced
ovarian cancer. Secondarily, we compared oncological out-
comes as well.
MATERIALS AND METHODS
After institutional review board approval, we retrospec-
tively reviewed the charts of patients who underwent sple-
nectomy with or without distal pancreatectomy at the time
of primary cytoreductive surgery for advanced ovarian can-
cer (International Federation of Gynecology and Obstetrics
[FIGO] stages IIIC-IV)15 at the European Institute of Oncol-
ogy in Milan. From January 2001 to December 2008, among
259 patients with advanced ovarian cancers who underwent
surgery, 33 cases were identified. Among all patients, we also
selected 99 additional matched cases (ratio, 1:3) by age,
American Society of Anesthesiology class, tumoral size (largest
tumor bulk), presence of peritoneal carcinosis (defined as the
presence of multiple tumoral implants on the peritoneal sur-
faces of the abdominal cavity, mostly in the upper abdomen),
histology, nuclear grade, and surgical procedure but who did
not undergo either splenectomy or pancreatectomy during the
primary cytoreductive surgery for ovarian cancer.
Data collected included patients’ age, all perioperative
details including residual tumor as well as pathologic find-
ings, FIGO stage, adjuvant therapy, and follow-up data.
Residual tumor was defined as maximal dimension of
single largest cancer nodule at the end of cytoreductive sur-
gery. Exclusion criteria included prior attempt of surgical
cytoreduction at another institution, patients with stage IIIC
disease based on nodal metastases alone, histology consistent
with nonepithelial ovarian malignancies or borderline tumors,
and neoadjuvant chemotherapy treatment.
Data collected were compared between the 2 groups
(splenectomy vs no splenectomy). The statistical analysis was
carried out by SPSS 15.0 software (SPSS Inc, Madrid, Spain).
All statistical tests were two-sided, and differences were con-
sidered statistically significant at P G 0.05. Disease-free sur-
vival was defined as the time interval from the date of surgery
to the date of the documented first recurrence of disease. If
there was no documented recurrence, disease-free survival
was calculated from the date of surgery to the date of last
follow-up or death, whichever occurred first. Overall survival
was defined as the time interval from date of surgery to the
date of death or last follow-up. The Kaplan-Meier method was
used to estimate survival curves, and differences in survival
were analyzed using the log-rank test.
RESULTS
Among the 132 records selected based on inclusion cri-
teria, 33 patients (25%) underwent splenectomy with or with-
out distal pancreatectomy (case group) and 99 (75%) did not
(control group) at the time of cytoreductive surgery. Baseline
TABLE 1. Baseline characteristics of patients and
malignancies
Characteristic
Case Group
n = 33
Control Group
n = 99 P
Age, mean T SD 54.8 T 10.7 55.2 T 9.7 ns
ASA class, % ns
I 6.1 7.1
II 27.2 40.8
III 66.7 52.1
IV 0 0
Size of largest mass,
mean T SD, cm
20.3 T 10.7 17.3 T 9.8 ns
Final FIGO stage, % G0.01
IIIC 51.5 76.8
IV 48.5 23.2
Peritoneal carcinosis, % 90.9 85.9 ns
Ascites, mean T
SD, mL
3205 T 2707 2174 T 2297 0.04
Preoperative CA125,
mean T SD, UI/mL
3049 T 5194 2959 T 6260 ns
Histology, % ns
Clear cells 6.1 1
Endometrioid 9.1 16.1
Serous 72.7 72.8
Mixed 12.1 10.1
Nuclear grade, % ns
1 3 4
2 24.2 14.2
3 63.6 79.8
N/A 9.2 2
ASA, American Society of Anesthesiology; n, number of cases;
N/A, not available; ns, not significant; SD, standard deviation.
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characteristics regarding patients and tumors of both groups
are shown in Table 1. We observed significant differences
between the groups with regard to final FIGO stage (48.5% vs
23.2% stage IV in the case group compared to the controls,
respectively; P G 0.01). Among all FIGO stage IV cases, we
observed 25% based on extra-abdominal lesions in the sple-
nectomy group versus 39.1% in the control group. We also ob-
served differences in the amount of ascites (3205 vs 2174 mL,
respectively; P = 0.04), although when we analyzed only the
serous tumors, no statistical differences were found (2952 vs
2409 mL, respectively; P = 0.35).
Both groups were also comparable with respect to
the surgical procedures performed. We did not observe any
difference between the groups, with the exception, besides
splenectomy, of distal pancreatectomy (Table 2). In the sple-
nectomy group, 4 distal pancreatectomies (12.1%) were car-
ried out, whereas, as expected, none in the control group
(P G 0.01). If we analyze only serous tumors, we also observe
a significant higher rate of small bowel resection in the sple-
nectomy group (12.5% vs 1.4%, respectively; P = 0.01). Com-
parison of perioperative characteristics is shown in Table 3.
We observed longer operating time in the splenectomy group
(33 extra minutes in case group, P = 0.02) as well as larger
estimated blood loss (812 extra milliliters in the case group,
P = 0.03) and consequently intraoperative blood transfusion
rate (78.8% vs 42.4% in the case group compared to the
controls, P G 0.01). The last 3 items seemed to be insignificant
when we analyzed only serous carcinomas. Intensive care unit
stay was also significantly longer in the splenectomy group
(1.4 T 1.3 days) compared to that in the control group (0.5 T
0.8 days). Moreover, residual tumor (Table 3), although not
statistically significant (P = 0.07), tends to be smaller in the
splenectomy group (mean of 7.1 mm) compared to the control
group (mean of 12.2 mm.). However, when we analyzed only
serous tumors, we observed statistical significance (5.3 T
6.9 mm in the splenectomy group vs 13.8 T 23.9 mm in the
controls; P = 0.008) and larger significant differences if we
subanalyzed grade 3 tumors (5.2 T 7.2 mm in the splenectomy
group vs 16.1 T 25.7 mm in the controls; P = 0.007).
We did not observe significant differences among most
postoperative complications, with the exception of pleural ef-
fusion rate, which was higher (P = 0.02) in the splenectomy
group, as well as the rate of postoperative pneumonia (P = 0.01)
(Table 4). When we selected grade 3 serous tumors, no sig-
nificant differences were observed in pleural effusion rates
(50% in the splenectomy group vs 28.1% in the controls;
P = 0.18). However, hospital stay was not significantly longer
in the splenectomy group.
The mean T SD follow-up time was 32 T 21.5 months
(30.2 T 20.7 months in the splenectomy group and 32.4 T 21.9
in the control group). The patients received a mean number
of cycles of chemotherapy of 5.6 T 2.2 in the splenectomy
group vs 6.4 T 1.8 cycles in the control group (P = 0.06). In
the first group, 75.8% received carboplatin + paclitaxel and
9.1% carboplatin + docetaxel, whereas in the control group,
the percentages were 74.7% and 8.1%, respectively. The rest
of the patients received other combinations of chemotherapy.
At the time of follow-up, we observed 33.3% and 36.4% of
patients alive with disease and dead of disease, respectively,
in the splenectomy group compared to 26.3% and 40.4%,
respectively, in the control group (P = 0.74). No significant
differences were found in disease free and overall survival
rates, which were 30.3% and 66.6%, respectively, in the sple-
nectomy group and 33.3% and 59.6%, respectively, in the
control group. Moreover, no differences were observed also
TABLE 2. Comparison of surgical procedures by group
Procedure
Case Group
n = 33, %
Control Group
n = 99, % P
TAH/BSO 97 100 ns
Rectosigmoid resection 72.7 62.6 ns
Small bowel resection 9.1 4 ns
Hemicolectomy L/R 6.1 5 ns
Transverse colectomy 6.1 4 ns
Ileocecal resection 6.1 8.1 ns
Total omentectomy 93.9 98 ns
Lymph nodes dissection 39.4 45.5 ns
Diaphragmatic surgery ns
Stripping 45.5 41.4
Resection 27.3 15.2
Distal pancreatectomy 12.1 0 G0.01
Liver resection 15.2 6.1 ns
Cholecystectomy 3 2 ns
Gastric resection 0 2 ns
Ileostomy 3 0 ns
Colostomy 0 1 ns
BSO, Bilateral salpingo-oophorectomy; L/R, left/right; TAH,
total abdominal hysterectomy.
TABLE 3. Perioperative features
Characteristics
Case
Group n = 33
(Mean T SD)
Control
Group n = 99
(Mean T SD) P
Mean RT, mm 7.1 T 10.5 12.2 T 21.9 0.07
Residual tumor, mm ns
0 42.4% 42.4%
0.1Y10 39.4% 37.4%
910 18.2% 20.2%
Operating time, min 305 T 62 272 T 72 0.02
EBL, mL 1828 T 1373 1016 T 983 0.03
Intraoperative BT 78.8% 42.4% G0.01
Postoperative BT 63.6% 52.5% ns
Parenteral nutrition 57.6% 43.4% ns
ICU stay, days 1.4 T 1.3 0.5 T 0.8 G0.01
Length of stay, days 11.1 T 5.7 9.5 T 3.3 ns
BT, Blood transfusion; EBL, estimated blood loss; ICU, intensive
care unit; RT, residual tumor.
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in the time to relapse between groups (13.8 T 10.9 months in
the splenectomy group vs 17.3 T 12.1 months in the control
group). Similarly, overall survival curves did not show sig-
nificant differences (P = 0.48) between the groups with the
log rank test as well (Fig. 1). Same results were observed after
a subanalysis on serous tumors and grade 3 tumors.
DISCUSSION
Primary cytoreductive surgery is the cornerstone of
the initial approach of patients with diagnosis of advanced
ovarian cancer (FIGO stages IIYIV); and because the goal of
such surgery should be the reduction to microscopic disease
of the whole malignancy,8 splenectomy should not be a lim-
itation to achieve such an aim when involved by disease.
Isolated splenic parenchymal lesions are rare. A litera-
ture search performed through Pubmed yielded only reports
of a few cases.10,16Y19 Several studies have proposed different
hypotheses to explain this phenomenon, most notably sug-
gesting that the splenic capsule could act as a shield. The con-
tractile properties of the spleen might also be involved, as
well as local splenic immunomechanisms. A suggested poor
development of afferent lymphatics to the spleen or perhaps
the tortuosity of the splenic artery could also be responsible of
the low involvement rate. Abdominal fluid circulation may
also explain the lower rate of carcinomatosis in the left upper
quadrant. Among isolated splenic metastasis, isolated splenic
parenchymal lesions are more infrequent and represent the
hematogenous spreading of the malignancy.10,17,18
Chen et al,20 in 2000, evaluated the role of splenectomy
at the time of surgical cytoreduction in advanced ovarian can-
cer and concluded that it could be performed with accept-
able morbidity. More authors in more recent years suggest to
incorporate upper abdominal resection in advanced ovarian
cancer to achieve a complete cytoreduction.21,22
We compared 2 groups of patients who underwent pri-
mary cytoreductive surgery, matched by clinical characteristics
and surgical procedures with the exception of splenectomy
with or without distal pancreatectomy, to evaluate the role of
spleen removal to achieve complete cytoreduction of peri-
operative characteristics and postoperative complications. To
our knowledge, this is the first paper that presents a case-
match design to address this issue.
The 2 groups were comparable; only FIGO stage IVand
ascites volume were significantly higher in the splenectomy
group, indirectly confirming the larger extent of disease in that
group, although in further analysis for serous tumors, ascites
seemed to be the same for both groups.
Concerning the perioperative features, we observed, as
expected, longer operative time, larger estimated blood loss,
and higher intraoperative blood transfusion rate in the sple-
nectomy group; an extra day of intensive care unit stay (ICU)
was also observed in the case group. The differences in op-
erative time could be not clinically relevant, although we con-
sider important the increase in blood loss and the stay in the
ICU unit in patients’ longer healing and higher hospital ex-
penses. These differences could be related to the presence of
a significant higher percentage of more advanced stage dis-
ease in this group. Slightly higher rates of procedures in the
upper abdomen were observed in the splenectomy group.
No complications associated to the 4 distal pancreatectomies
performed in the group of splenectomy were observed. De-
spite of longer ICU stay for the splenectomy group, no sig-
nificant differences were noted in total length of hospital stay.
The most common complications related to splenectomy
reported in the literature are left-sided atelectasis, thromboem-
bolic events, and pneumonia.23,24 Magtibay et al24 reported
on 112 splenectomies (66 at primary cytoreduction for ad-
vanced ovarian cancer), and the perioperative morbidity and
mortality rates were 15% and 5%, respectively, with none of
the deaths directly related to the splenectomy.25
TABLE 4. Postoperative complications
Complications
Case Group
n = 33, n (%)
Control Group
n = 99, n (%) P
Anastomotic leak 1 (3) 2 (2) ns
Pelvic abscess 0 (0) 2 (2) ns
UTI 1 (3) 2 (2) ns
Wound infection 3 (9.1) 5 (5.1) ns
Thromboembolism 2 (6.1) 1 (1) ns
Pleural effusion 15 (45.5) 19 (19.2) 0.02
Pneumothorax 3 (9.1) 6 (6.1) ns
Subphrenic abscess 1 (3) 1 (1) ns
Pneumonia 2 (6.1) 0 (0) 0.01
Sepsis 1 (3) 1 (1) ns
Others
Cardiovascular 3 (9.1) 5 (5.1) ns
Urinary 1 (3) 3 (3) ns
Gastrointestinal 1 (3) 7 (7.1) ns
Nerve injury 1 (3) 2 (2) ns
UTI, Urinary tract infection.
FIGURE 1. Comparison between splenectomy group
and control group of overall survival curves calculated by
Kaplan-Meier method (P = 0.48).
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Regarding postoperative complications, we did not
observe significant differences between groups, with the ex-
ception of a significant higher pleural effusion and pneu-
monia rate observed in the splenectomy group. The former
may be related to the extent of the disease in the upper ab-
domen, with a higher rate of diaphragm involvement. In fact,
although the difference was not statistically significant be-
tween the groups, we observed a larger number of patients
who underwent diaphragmatic stripping and resection in the
splenectomy group compared to the controls. Moreover, the
larger ascites volume in the splenectomy group (mean of
3205 vs 2174 mL, respectively; P = 0.04) supports the hy-
pothesis that in this group, more disseminated disease could
be present. We also observed 6.1% patients who developed
postoperative pneumonia in the splenectomy group compared
to 0% in the control, may be due to the absence of the spleen,
which contains the largest reserve of the body’s monocytes
and, together with the activity of the reticuloendothelial sys-
tem, promotes the tissue healing and avoids the infections by
capsulate bacterias.26 Our results are very close to the data
reported by Magtibay et al,24 who describe 4.4% of pneu-
monia and 4.4% of sepsis (3% in our case group). Similarly,
Chi et al27 published on 45 splenectomies and described that
a higher rate of pneumonia may be caused by the splenec-
tomy; however, the removal of the involved spleen to achieve
a complete primary cytoreduction increases the overall sur-
vival rate in these patients.8,28
In the present study, the remaining postoperative com-
plication rates are acceptable and similar in the 2 groups.
Again, despite a higher rate of pleural effusion and pneu-
monia for the splenectomy group, no significant differences
were noted in total length of hospital stay.
Moreover, residual tumor, although not statistically
significant (P = 0.07), tends to be smaller in the splenectomy
group compared to the control group; and probably with
larger groups of patients, this difference could reach statistical
significance. Moreover, after selection of serous and grade 3
tumors, significant differences were observed. This difference
has a special interest, as cytoreduction to nodules less than
1 cm in maximum diameter seems to be associated with a
clear benefit of overall survival compared to those cases with
larger residual disease.8,28 In this study, we found same rates
of residual tumor less than 1 cm: 81.1% in the splenectomy
group versus 79.8% in the control group (87.5% vs 78.8%,
respectively, for serous tumors).
In the current study, we did not observe differences
between the groups in the disease-free survival and overall
survival rates. We believe this represents a positive result of
oncological outcomes, as the splenectomy group had a sig-
nificant higher rate (25.3%) of FIGO stage IV disease usually
believed to have a poorer prognosis than stage IIIC.29 There-
fore, the amount of residual disease at the end of primary
cytoreductive surgery rather than initial bulk of tumor seems
to be a more significant prognostic factor for oncology out-
comes of these groups of patients.
Other studies observed that patients with ovarian can-
cer with splenic metastasis presented a poorer prognosis than
those without splenic metastasis; but again, the difference was
not statistically significant.30,31
In conclusion, splenectomy, with distal pancreatectomy
if pancreatic tail is involved, at the time of primary cytore-
ductive surgery for patients with advanced ovarian cancer
may contribute to achieve complete cytoreduction with ac-
ceptably low perioperative complication and mortality rates.
Therefore, this procedure seems to be an acceptable and fea-
sible intervention in the effort to achieve no residual disease
and therefore to improve the oncologic outcomes of these
patients.
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